Patents by Inventor Andre Choulika

Andre Choulika has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180237798
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 23, 2018
    Applicant: Cellectis
    Inventors: Philippe DUCHATEAU, Andre CHOULIKA, Laurent POIROT
  • Patent number: 9890393
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: February 13, 2018
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, André Choulika, Laurent Poirot
  • Patent number: 9855297
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 2, 2018
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, André Choulika, Laurent Poirot
  • Publication number: 20170037434
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 9, 2017
    Inventors: Andre Choulika, Richard C. Mulligan
  • Patent number: 9458439
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 4, 2016
    Assignees: Children's Medical Center Corporation, Institut Pasteur
    Inventors: Andre Choulika, Richard C. Mulligan
  • Publication number: 20160272999
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Application
    Filed: April 1, 2014
    Publication date: September 22, 2016
    Inventors: Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
  • Publication number: 20160184362
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 30, 2016
    Applicant: Cellectis
    Inventors: Philippe DUCHATEAU, André CHOULIKA, Laurent POIROT
  • Patent number: 9365864
    Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: June 14, 2016
    Assignee: CELLECTIS
    Inventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
  • Publication number: 20150315557
    Abstract: An I-CreI variant, wherein at least one of the two I-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection.
    Type: Application
    Filed: June 19, 2015
    Publication date: November 5, 2015
    Applicant: CELLECTIS
    Inventors: Andre Choulika, Frederic Cedrone, Julianne Smith
  • Publication number: 20150259655
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Application
    Filed: November 21, 2014
    Publication date: September 17, 2015
    Inventors: Andre Choulika, Richard C. Mulligan
  • Patent number: 8921332
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: December 30, 2014
    Assignees: Children's Medical Center Corporation, Institut Pasteur
    Inventors: André Choulika, Richard C. Mulligan
  • Publication number: 20140178942
    Abstract: Meganuclease variants which cleave at least one target in the provirus of a retrovirus and in particular which cleave the genomic insertion of the provirus. The present invention particular relates to meganuclease variants which cleave the provirus of the Human Immunodeficiency Virus genome following genomic insertion. Vector encoding such variants, as well as to a cell or multi-cellular organism modified by such a vector and use of said meganuclease variants and derived products for genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy.
    Type: Application
    Filed: October 28, 2013
    Publication date: June 26, 2014
    Applicant: CELLECTIS
    Inventors: ANDRE CHOULIKA, ROMAN GALETTO
  • Publication number: 20140121115
    Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 1, 2014
    Applicant: Cellectis
    Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Phillipe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, Davie Sourdive
  • Publication number: 20140004608
    Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.
    Type: Application
    Filed: May 22, 2013
    Publication date: January 2, 2014
    Applicant: CELLECTIS
    Inventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
  • Patent number: 8476072
    Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: July 2, 2013
    Assignee: Cellectis
    Inventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
  • Publication number: 20120260356
    Abstract: Meganuclease variants which cleave at least one target in the provirus of a retrovirus and in particular which cleave the genomic insertion of the provirus. The present invention in particular relates to meganuclease variants which cleave the provirus of the Human Immunodeficiency Virus genome following genomic insertion. Vector encoding such variants, as well as to a cell or multi-cellular organism modified by such a vector and use of said meganuclease variants and derived products for genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy.
    Type: Application
    Filed: April 21, 2010
    Publication date: October 11, 2012
    Applicant: CELLECTIS
    Inventors: André Choulika, Roman Galetto
  • Publication number: 20120230971
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.
    Type: Application
    Filed: March 12, 2012
    Publication date: September 13, 2012
    Applicants: INSTITUT PASTEUR, CHILDREN'S MEDICAL CENTER, CORP.
    Inventors: ANDRÉ CHOULIKA, RICHARD C. MULLIGAN
  • Publication number: 20120171191
    Abstract: An I-CreI variant, wherein at least one of the two 1-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection.
    Type: Application
    Filed: May 26, 2010
    Publication date: July 5, 2012
    Applicant: CELLECTIS
    Inventors: André Choulika, Frédéric Cedrone, Julianne Smith
  • Publication number: 20120165400
    Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.
    Type: Application
    Filed: May 5, 2011
    Publication date: June 28, 2012
    Applicants: The Children's Medical Center Corporation, The Institute Pasteur
    Inventors: André Choulika, Richard C. Mulligan
  • Patent number: 8206965
    Abstract: This patent application relates to hybrid and/or single-chain rare-cutting endonucleases, called meganucleases, which recognize and cleave a specific nucleotide sequence, to polynucleotide sequences encoding for said rare-cutting endonucleases, to a vector comprising one of said polynucleotide sequences, to a cell or animal comprising one of said polynucleotide sequences or said rare-cutting endonucleases, to a process for producing one of said rare-cutting endonucleases and any use of the disclosed products and methods. More particularly, this invention contemplates any use of such rare-cutting endonuclease for genetic engineering and gene therapy.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: June 26, 2012
    Assignee: Cellectis S.A.
    Inventors: Sylvain Arnould, Patrick Chames, Andre Choulika, Jean-Charles Epinat, Emmanuel Lacroix